JP Morgan Chase’s Orgenesis Inc. Common Stock ORGS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-9
| Closed | -$40 | – | 7880 |
|
|
2024
Q3 | $40 | Sell |
9
-7
| -44% | -$47 | ﹤0.01% | 7158 |
|
|
2024
Q2 | $95 | Hold |
16
| – | – | ﹤0.01% | 6902 |
|
|
2024
Q1 | $127 | Buy |
16
+2
| +14% | +$11 | ﹤0.01% | 6873 |
|
|
2023
Q4 | $71 | Buy |
14
+1
| +8% | +$6 | ﹤0.01% | 7160 |
|
|
2023
Q3 | $79 | Buy |
13
+3
| +30% | +$27 | ﹤0.01% | 6940 |
|
|
2023
Q2 | $132 | Sell |
10
-203
| -95% | -$2.41K | ﹤0.01% | 6676 |
|
|
2023
Q1 | $3K | Buy |
213
+203
| +2,030% | +$3.81K | ﹤0.01% | 6370 |
|
|
2022
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 7106 |
|
|
2022
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 6951 |
|
|
2022
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 6985 |
|
|
2022
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 7112 |
|
|
2021
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 7042 |
|
|
2021
Q3 | $0 | Sell |
10
-4,526
| -100% | -$227K | ﹤0.01% | 6888 |
|
|
2021
Q2 | $230K | Sell |
4,536
-1,721
| -28% | -$86.7K | ﹤0.01% | 5167 |
|
|
2021
Q1 | $358K | Buy |
6,257
+345
| +6% | +$22.5K | ﹤0.01% | 4871 |
|
|
2020
Q4 | $266K | Buy |
5,912
+3,787
| +178% | +$182K | ﹤0.01% | 4703 |
|
|
2020
Q3 | $106K | Buy |
2,125
+502
| +31% | +$27.2K | ﹤0.01% | 4662 |
|
|
2020
Q2 | $99K | Buy |
+1,623
| New | +$98.2K | ﹤0.01% | 4583 |
|
JP Morgan Chase's ORGS Position: Q4 2024 in Review
JP Morgan Chase sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2024, closing a stake of 9 shares — an estimated $40 sold.
JP Morgan Chase first reported a position in ORGS in Q2 2020 and held it in 18 quarters. The position peaked at $358K in Q1 2021. 0 funds tracked by Wall St. Rank hold ORGS as of Q4 2024.
- JP Morgan Chase reported no remaining Orgenesis Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- JP Morgan Chase sold 9 Orgenesis Inc. Common Stock shares in Q4 2024, an estimated $40.
- JP Morgan Chase first reported a position in Orgenesis Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- JP Morgan Chase's Orgenesis Inc. Common Stock position peaked at $358K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2024.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.